Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells

Molecular and Cellular Endocrinology

Volumn 331, Issue 1, 2011, Pages 57-65

  Makkonen, Harri ^a   Kauhanen, Miia ^a   Jääskeläinen, Tiina ^a   Palvimo, Jorma J ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Androgen receptor; Antiandrogen; Chromatin immunoprecipitation (ChIP); Gene expression; Prostate cancer cell; VCaP

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; DIARYLTHIOHYDANTOIN; MESSENGER RNA; THIOHYDANTOIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL; CELL STRAIN LNCAP; CHROMATIN; CONTROLLED STUDY; DOWN REGULATION; ENHANCER REGION; GENE EXPRESSION; GENE INTERACTION; GENE LOCUS; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; SENSITIVITY ANALYSIS; VERTEBRAL CANCER OF THE PROSTATE CELL;

ANDROGENS; ANILIDES; CELL LINE, TUMOR; CHROMATIN; CYPROTERONE ACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; METRIBOLONE; NITRILES; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS; TRANSCRIPTION, GENETIC;

EID: 78149411481     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.08.008     Document Type: Article

References (49)

1. Amler L.C., Agus D.B., LeDuc C., Sapinoso M.L., Fox W.D., Kern S., Lee D., Wang V., Leysens M., Higgins B., Martin J., Gerald W., Dracopoli N., Cordon-Cardo C., Scher H.I., Hampton G.M. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000, 60:6134-6141.
2. Averboukh L., Liang P., Kantoff P.W., Pardee A.B. Regulation of S100P expression by androgen. Prostate 1996, 29:350-355.
3. Bieberich C.J., Fujita K., He W.W., Jay G. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J. Biol. Chem. 1996, 271:31779-31782.
4. Bohl C.E., Wu Z., Miller D.D., Bell C.E., Dalton J.T. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J. Biol. Chem. 2007, 282:13648-13655.
5. Bolton E.C., So A.Y., Chaivorapol C., Haqq C.M., Li H., Yamamoto K.R. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 2007, 21:2005-2017.
6. Bonkhoff H., Berges R. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010, 70:100-112.
7. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
8. Culig Z., Bartsch G., Hobisch A., Comuzzi B., Steiner H. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92:265-271.
9. Dehm S.M., Tindall D.J. Molecular regulation of androgen action in prostate cancer. J. Cell. Biochem. 2006, 99:333-344.
10. Gao W., Bohl C.E., Dalton J.T. Chemistry and structural biology of androgen receptor. Chem. Rev. 2005, 105:3352-3370.
11. Gao N., Zhang J., Rao M.A., Case T.C., Mirosevich J., Wang Y., Jin R., Gupta A., Rennie P.S., Matusik R.J. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 2003, 17:1484-1507.
12. Gregory C.W., Hamil K.G., Kim D., Hall S.H., Pretlow T.G., Mohler J.L., French F.S. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res. 1998, 58:5718-5724.
13. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., Wilson E.M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61:4315-4319.
14. Han G., Buchanan G., Ittmann M., Harris J.M., Yu X., Demayo F.J., Tilley W., Greenberg N.M. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1151-1156.
15. Heemers H.V., Tindall D.J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 2007, 28:778-808.
16. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25:276-308.
17. Henshall S.M., Quinn D.I., Lee C.S., Head D.R., Golovsky D., Brenner P.C., Delprado W., Stricker P.D., Grygiel J.J., Sutherland R.L. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001, 61:423-427.
18. Karvonen U., Jänne O.A., Palvimo J.J. Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei. FEBS Lett. 2002, 523:43-47.
19. Karvonen U., Jänne O.A., Palvimo J.J. Androgen receptor regulates nuclear trafficking and nuclear domain residency of corepressor HDAC7 in a ligand-dependent fashion. Exp. Cell Res. 2006, 312:3165-3183.
20. Karvonen U., Kallio P.J., Jänne O.A., Palvimo J.J. Interaction of androgen receptors with androgen response element in intact cells. Roles of amino- and carboxyl-terminal regions and the ligand. J. Biol. Chem. 1997, 272:15973-15979.
21. Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., Trapman J., Cleutjens K., Noordzij A., Visakorpi T., Kallioniemi O.P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997, 57:314-319.
22. Korenchuk S., Lehr J.E., MClean L., Lee Y.G., Whitney S., Vessella R., Lin D.L., Pienta K.J. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001, 15:163-168.
23. Krongrad A., Wilson C.M., Wilson J.D., Allman D.R., McPhaul M.J. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Mol. Cell. Endocrinol. 1991, 76:79-88.
24. Kuil C.W., Mulder E. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens. Endocrinology 1996, 137:1870-1877.
25. Lamont K.R., Tindall D.J. Androgen regulation of gene expression. Adv. Cancer Res. 2010, 107:137-162.
26. Li R., Wheeler T., Dai H., Frolov A., Thompson T., Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am. J. Surg. Pathol. 2004, 28:928-934.
27. Lin B., Ferguson C., White J.T., Wang S., Vessella R., True L.D., Hood L., Nelson P.S. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999, 59:4180-4184.
28. Linja M.J., Tammela T.L., Vessella R.L., Savinainen K.J., Saramäki O.R., Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61:3550-3555.
29. Liu W., Xie C.C., Zhu Y., Li T., Sun J., Cheng Y., Ewing C.M., Dalrymple S., Turner A.R., Sun J., Isaacs J.T., Chang B.L., Zheng S.L., Isaacs W.B., Xu J. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 2008, 10:897-907.
30. Makkonen H., Kauhanen M., Paakinaho V., Jääskeläinen T., Palvimo J.J. Long-range activation of FKBP51 transcription by the androgen receptor via distal intronic enhancers. Nucleic Acids Res. 2009, 37:4135-4148.
31. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., True L.D., Nelson P.S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008, 68:4447-4454.
32. Mostaghel E.A., Page S.T., Lin D.W., Fazli L., Coleman I.M., True L.D., Knudsen B., Hess D.L., Nelson C.C., Matsumoto A.M., Bremner W.J., Gleave M.E., Nelson P.S. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007, 67:5033-5034.
33. Ngan S., Stronach E.A., Photiou A., Waxman J., Ali S., Buluwela L. Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 2009, 28:2051-2063.
34. Nitsche E.M., Moquin A., Adams P.S., Guenette R.S., Lakins J.N., Sinnecker G.H., Kruse K., Tenniswood M.P. Differential display RT PCR of total RNA from human foreskin fibroblasts for investigation of androgen-dependent gene expression. Am. J. Med. Genet. 1996, 63:231-238.
35. Oosterhoff J.K., Grootegoed J.A., Blok L.J. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling. Endocr. Relat. Cancer 2005, 12:135-148.
36. Paakinaho V., Makkonen H., Jääskeläinen T., Palvimo J.J. Glucocorticoid receptor activates poised FKBP51 locus through long-distance interactions. Mol. Endocrinol. 2010, 24:511-525.
37. Rosner I.L., Ravindranath L., Furusato B., Chen Y., Gao C., Cullen J., Sesterhenn I.A., McLeod D.G., Srivastava S., Petrovics G. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy. Urology 2007, 70:1225-1229.
38. Schuur E.R., Henderson G.A., Kmetec L.A., Miller J.D., Lamparski H.G., Henderson D.R. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem. 1996, 271:7043-7051.
39. Shan L.X., Rodriguez M.C., Jänne O.A. Regulation of androgen receptor protein and mRNA concentrations by androgens in rat ventral prostate and seminal vesicles and in human hepatoma cells. Mol. Endocrinol. 1990, 4:1636-1646.
40. Shi X.B., Xue L., Zou J.X., Gandour-Edwards R., Chen H., deVere White R.W. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells. Prostate 2008, 68:1816-1826.
41. Stewart A.B., Lwaleed B.A., Douglas D.A., Birch B.R. Current drug therapy for prostate cancer: an overview. Curr. Med. Chem. Anticancer Agents 2005, 5:603-612.
42. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., Yu J., Wang L., Montie J.E., Rubin M.A., Pienta K.J., Roulston D., Shah R.B., Varambally S., Mehra R., Chinnaiyan A.M. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
43. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
44. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J., Smith-Jones P.M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C.D., Higano C.S., Beer T.M., Hung D.T., Scher H.I., Jung M.E., Sawyers C.L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
45. Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 1990, 173:534-540.
46. Waltering K.K., Helenius M.A., Sahu B., Manni V., Linja M.J., Jänne O.A., Visakorpi T. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009, 69:8141-8149.
47. Wang Q., Li W., Liu X.S., Carroll J.S., Jänne O.A., Keeton E.K., Chinnaiyan A.M., Pienta K.J., Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 2007, 27:380-392.
48. Young C.Y., Montgomery B.T., Andrews P.E., Qui S.D., Bilhartz D.L., Tindall D.J. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res. 1991, 51:3748-3752.
49. Yu J., Yu J., Mani R.S., Cao Q., Brenner C.J., Cao X., Wang X., Wu L., Li J., Hu M., Gong Y., Cheng H., Laxman B., Vellaichamy A., Shankar S., Li Y., Dhanasekaran S.M., Morey R., Barrette T., Lonigro R.J., Tomlins S.A., Varambally S., Qin Z.S., Chinnaiyan A.M. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010, 17:443-454.